---
figid: PMC8340210__ajtr0013-7427-f2
figtitle: Development of PARP inhibitor combinations for castration resistant prostate
  cancer unselected for homologous recombination repair mutations
organisms:
- Homo sapiens
pmcid: PMC8340210
filename: ajtr0013-7427-f2.jpg
figlink: /pmc/articles/PMC8340210/figure/fig02/
number: F2
caption: A. Cells treated with Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors (PARPi)
  have increased activation of the AKT survival pathway. Cederanib is able to decrease
  the translation of homologous recombination proteins through a hypoxia-dependent
  mechanism by inhibiting vascular endothelial growth factor receptor (VEGFR) and
  platelet derived growth factor receptor (PDFGFR) signaling. B. PARP1/2 have been
  shown to bind to pioneering transcription factors and change the chromatin landscape
  of cells to allow the androgen receptor (AR) to bind to prostate-cancer-specific
  enhancers.
papertitle: Development of PARP inhibitor combinations for castration resistant prostate
  cancer unselected for homologous recombination repair mutations.
reftext: Taylor Ryan McFarland, et al. Am J Transl Res. 2021;13(7):7427-7439.
year: '2021'
doi: ''
journal_title: American Journal of Translational Research
journal_nlm_ta: Am J Transl Res
publisher_name: e-Century Publishing Corporation
keywords: Metastatic prostate cancer | PARP | BRCA | immunotherapy | olaparib | rucaparib
  | talazoparib | androgen receptor
automl_pathway: 0.958501
figid_alias: PMC8340210__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8340210__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8340210__ajtr0013-7427-f2.html
  '@type': Dataset
  description: A. Cells treated with Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors
    (PARPi) have increased activation of the AKT survival pathway. Cederanib is able
    to decrease the translation of homologous recombination proteins through a hypoxia-dependent
    mechanism by inhibiting vascular endothelial growth factor receptor (VEGFR) and
    platelet derived growth factor receptor (PDFGFR) signaling. B. PARP1/2 have been
    shown to bind to pioneering transcription factors and change the chromatin landscape
    of cells to allow the androgen receptor (AR) to bind to prostate-cancer-specific
    enhancers.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FOXA1
  - PARP2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - PDGFRB
  - PDGFRA
  - KDR
  - FLT1
  - FLT4
  - AR
---
